Novo Nordisk
NVO·NYSENextSignal Score™
AI-powered rating
Stock Analysis Summary
Moderates Umsatzwachstum, Positives EPS-Wachstum, Hohe Bruttomarge, Starke Eigenkapitalrendite.
KGV 11.5 – günstig, KUV attraktiv, KBV attraktiv, Analysten neutral.
Negativer Trend, Beta 1.85 – hohe Volatilität.
Abwärtstrend aktiv.
RSI 44.8 – neutrales Momentum.
Novo Nordisk stock is currently trading at $37.82, placing it in a phase of technical consolidation.
🚀 What is happening currently?
Novo Nordisk is in a complex transformation phase, as the company attempts to regain lost ground by diversifying its pipeline and expanding its Wegovy pill business. Recent clinical data, such as that for CagriSema and the use of Wegovy in children, underscore the group's medical innovation power. Nevertheless, the market environment remains characterized by intense competition and pricing pressure on GLP-1 preparations. Investors are currently watching closely to see whether the raised annual forecast and operational discipline are sufficient to initiate a sustainable recovery, while the increased risk posed by the patent expiration of semaglutide in 2032 remains in focus.
🔍 Technical Analysis
At a price of $37.82, the stock is trading significantly below the EMA20 ($39.97), the EMA50 ($40.62), and the EMA200 ($45.09), confirming the overarching downward trend. The 52-week high is at $64.16, while the 52-week low of $35.12 represents an important psychological level. The RSI of 38.6 signals a neutral to slightly weak condition without reaching oversold territory. As the MACD (-0.100) is below its signal (0.160), momentum continues to weaken. The next support levels are at $$36.85,35.85, and $35.12, while resistance levels are forming at $$39.88,43.24, and $46.05.
📊 Fundamental Situation
The company has adjusted its forecast for 2026 several times and now expects adjusted revenue and operating profit to fluctuate between a 2% decline and 2% growth. The quarterly figures for the third quarter of 2026 showed a solid operational performance, although the stock is driven more by long-term future expectations than by current profitability. Fundamental data is partially incomplete and should be interpreted with caution, as the effects of US pricing and pipeline development costs are influencing margins.
🎯 Analyst Expectations
The average analyst price target is $45.73, implying an upside potential of approximately 20.92%. The consensus analyst rating is "Hold," reflecting a cautious stance on short-term price performance.
💡 Market Assessment
The NextSignal Score of 52/100 rates the stock as neutral. This evaluation reflects the discrepancy between positive clinical progress and the technically damaged condition. As the price remains below the key moving averages, no clear trend is currently discernible. Investors should wait for further developments in margins and the market launch of new products before assuming a trend reversal. A neutral position seems appropriate given the current data.
🔍 What to watch for
- US pricing trends: The effects of price pressure on injectable GLP-1 preparations in the US are crucial for margin development.
- CagriSema approval: The FDA's decision on the approval of CagriSema is a key milestone for the pipeline strategy.
- 2027 quarterly figures: The upcoming results on 03.02.2027 will show whether the operational recovery is gaining momentum.
Technical analysis
Last 60 trading days · Live data from Yahoo Finance
- • Price action over the last few weeks at a glance.
- • EMA lines help identify the prevailing trend direction.
Fundamentals & News
Live dataCompany

Novo Nordisk A/S
Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd. Its core business focuses on the research, development, and manufacturing of medications for the treatment of diabetes as well as other serious chronic conditions, including obesity and rare blood and endocrine disorders.
Fundamentals
Key metrics
Latest News
Recent reports
Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?
Eli Lilly Is Near Its High. Bank of America Sees Another 19%
Novo Gets FDA Approval For First-Of-Its-Kind Weekly Growth Hormone Treatment For Children With Turner Syndrome
Novo's Sogroya® receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner Syndrome (TS)
Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?
Forget the Headlines: Novo Nordisk's (NVO) 4.6% Dividend Yield Is the Real Story for Patient Investors

